In Japan, L-asparaginase is approved for use in pediatric ALL, but is associated with allergic reactions in some patients, meaning they need to discontinue this element of the therapy, which impacts on their prognosis. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.